|
|
|
|
|
|
|
|
search results (77)
Site
Search returned 77 results for “ovarian cancer”
-
Poster
2016 ASCO Annual Meeting Poster Session Glucocorticoid receptor expression and survival in ovarian cancer.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Discussion Session Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session Validation of a multi-marker panel for early detection of ovarian cancer.June 3, 2016 -
Poster
-
Poster
-
Poster
2016 ASCO Annual Meeting Poster Session Circulating cell-free DNA: The future of personalized medicine in ovarian cancer management.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session P53 functional mutation type in high grade serous ovarian cancer and clinical outcomes.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session Endocrine therapy for ovarian cancer: A systematic review and meta-analysis of phase II studies.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session A Phase Ib study of Acelarin and carboplatin for patients with recurrent ovarian cancer.June 3, 2016 -
Poster
-
Poster
-
Poster
2016 ASCO Annual Meeting Poster Session Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: Colorectal cancer survival by trial arm.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session Randomized trial of exercise vs. usual care on cancer biomarkers in ovarian cancer survivors: The Women’s Activity and Lifestyle Study in Connecticut (WALC).June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Platinum Resistant Ovarian Cancer.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session Evolution in epithelial ovarian cancer (OC) trials: Improving accuracy by design.June 3, 2016 -
Poster
Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer.
2016 ASCO Annual Meeting Poster Session Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.June 3, 2016 -
Poster
2016 ASCO Annual Meeting Poster Session MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.June 3, 2016 -
Poster
-
Poster
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.